a Dimerization is a useful tool to boost ligand-receptor interaction. Both lipidation and dimerization effectively prolong the short half-life (t 1/2 ) of peptides by facilitating binding with serum albumin and increasing hydrodynamic size. Here, we described two novel GLP-1 conjugates with high glucagon-like peptide-1 (GLP-1) receptor activation potencies, dimerized GLP-1 (Di-GLP-1) and lipidated Di-GLP-1 (Lip-Di-GLP-1). Di-GLP-1 and Lip-Di-GLP-1 were prepared through cysteine-maleimide specific coupling reactions using Gly 8 -Cys 31 -GLP-1, bis-maleimide amine, and activated palmitic acid. The receptor activation potencies of Di-GLP-1 and Lip-Di-GLP-1 were 13.6-fold and 9.5-fold higher than GLP-1, respectively. The in vivo hypoglycemic and insulinotropic activities of Di-GLP-1 and Lip-Di-GLP-1
Introduction
Glucagon-Like Peptide-1 (GLP-1), a naturally occurring incretin hormone, is secreted from intestinal L-cells into the blood stream in response to nutrient intake.
1 GLP-1 is a potent antihyperglycemic hormone possessing multiple endocrine actions. The stimulation of insulin secretion by GLP-1 is glucosedependent with suppressed glucagon secretion. The glucosedependent action of GLP-1 is particularly attractive as GLP-1 no longer stimulates insulin secretion when the fasting blood glucose level is in the normal range to avoid hypoglycemia. 2, 3 Moreover, GLP-1 stimulates the differentiation and proliferation of insulinsecreting b-cells and inhibits pancreatic b-cell apoptosis. 4 In addition, GLP-1 is also known to inhibit gastric secretion and motility which contributes to a satiating effect through delays carbohydrate absorption. Furthermore, GLP-1 could lowering body weight through reducing caloric consumption and feelings of hunger in humans, including overweight people with type 2 diabetes. 5 In conclusion, GLP-1 is a promising therapeutic agent that could stabilize or reverse disease progression of type 2 diabetes mellitus (T2DM). However, early attempts to use GLP-1 for the treatment of T2DM met with limited success, due to the short biological half-life of GLP-1. GLP-1 is rapidly degraded in vivo due to rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV) and renal clearance. Thus, numerous research efforts were mainly focused on the development of stable GLP-1 analogs and/ or the sustained delivery of these analogs. 6 In nature, dimeric interactions are frequently occurred to improve the affinity of ligand-receptor interactions. 7 Thus, the possibility of using this strategy to improve the therapeutic potencies of peptide has attracted the interest of researchers. As a result, many research groups have using this strategy to produce peptides with enhanced interactions between ligands and target cells. Lee et al. designed dimer exendin-4 analog with enhanced receptor binding activities, and further PEGylation of dimer exendin-4 analog successfully improved its in vivo longacting antidiabetic activities. drugs. 9 Lipidization promotes the binding of peptides to albumin through conjugating fatty acid to the peptide sequence. Binding to human serum albumin (HSA) facilitating peptides being sterically shielded from enzyme degradation and rapid renal ltration due to the large molecular weight of HSA.
10
However, lipidization increases the lipophilicity of the peptide and may bring solubility issues. The fatty acid moiety, especially for very long fatty acids, may hamper the peptide-receptor interactions, leading to the decreased bioactivities.
11
In our previous research, we have successful combined dimerization and lipidization strategies to discover novel Xenopus GLP-1 analogues with improved biological activities and stabilities.
12
Considering the similar structure of Xenopus GLP-1 analogues and native GLP-1, we hypothesized that combined dimerization and lipidization strategies was also suitable applied to native GLP-1 to discover novel potent GLP-1 receptor (GLP-1R) agonists with enhanced metabolic stability. In this article, we prepared novel dimerized GLP-1 (Di-GLP-1) and fatty acid conjugated dimerized GLP-1 (Lip-Di-GLP-1, Fig. 1A ). The stability of synthesized analogs and their abilities to activate the GLP-1R in vitro, in vivo hypoglycemic and insulinotropic activities were examined. The gastric emptying, anorectic action, long-acting glucose lowering activities and long-term treatment efficacies of Lip-Di-GLP-1 in normal and diabetic mouse models (db/db) were also explored.
Results and discussion
Preparation and characterization of Di-GLP-1 and Lip-Di-GLP-1
Dimeric strategy was wildly occurred in nature, to investigate whether this strategy could also employed on GLP-1 to improve the biological activities and stabilities, Di-GLP-1 and Lip-Di-GLP-1 were designed and synthesized as described above. The apparent molecular weights (M w ) of Di-GLP-1 and Lip-Di-GLP-1 were determined by MS. As shown in Fig. S3 and 4 , Tables S1  and S2 (see ESI †) , their calculated mass-to-charge (m/z) ratios closely matched experimental values.
Biological activity tests of Di-GLP-1 and Lip-Di-GLP-1
The receptor activation potencies of Di-GLP-1 and Lip-Di-GLP-1 were examined in HEK293 cells, which stable expressed high levels of GLP-1R. As shown in Fig. 1B To investigate whether the higher GLP-1R potencies of Di-GLP-1 and Lip-Di-GLP-1 indicated higher in vivo hypoglycemic effects, we compared their acute glucose-lowering effects in normal Kunming mice by intraperitoneal glucose tolerance test (IPGTT). As shown in The insulinotropic effect of native GLP-1 is key physiologic function that leading insulin secretion in a blood glucose level- dependent manner. 13 To examine this function of Di-GLP-1 and Lip-Di-GLP-1, their antidiabetic and insulinotropic activities were examined in db/db mice, a type 2 diabetic model. As shown in Fig. 1D , treatment with Di-GLP-1 and Lip-Di-GLP-1 signicantly lower the blood glucose concentrations post the glucose challenge, and the AUC values of glucose showed that the hypoglycemic activities of Di-GLP-1 and Lip-Di-GLP-1 were similar and were signicantly better than GLP-1, liraglutide (chemical) and liraglutide (biotechnological) (P < 0.001 and P < 0.001, respectively). Accordingly, Di-GLP-1 and Lip-Di-GLP-1 were found exhibited signicantly better insulinotropic activities than GLP-1, liraglutide (chemical) and liraglutide (biotechnological) (P < 0.001 and P < 0.001, respectively, Fig. 1E ).
In vitro and in vivo toxicity assays MTT assay was performed on INS-1 cells as a preliminary evaluation of in vitro toxicity of Di-GLP-1 and Lip-Di-GLP-1. As shown in Fig. 2A and B, no prominent toxicity effects of Di-GLP-1 and Lip-Di-GLP-1 on INS-1 cells were observed under concentrations of 10, 100 and 1000 nM. The in vivo toxicity study was evaluated in db/db mice. Mice were twice daily s.c. injected saline, 500 nmol kg
(chemical) and liraglutide (biotechnological) for 7 days. At the end of the study, four key parameters indicative of liver toxicity (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)) and renal toxicity (blood urea nitrogen (BUN) and serum creatinine (SCr)) were determined by using automatic biochemical analyzer. As shown in Fig compared with mice treated with synthesized liraglutide, indicated the longer duration of hypoglycemic of Lip-Di-GLP-1 than synthesized liraglutide. Next, we performed a dose-response study to examine the dose dependency of the hypoglycemic effect of Lip-Di-GLP-1.
As shown in Fig. 3B and C, accompanied by the rise in the dose of Lip-Di-GLP-1, the rebound time from the nadir to the high glucose level signicantly increased, indicated Lip-Di-GLP-1 had a dose-dependent long-acting glucose-lowering efficacy. Compared with Lip-Di-GLP-1, synthesized liraglutide showed a less potent and shorter duration of hypoglycemic activities.
Gastric emptying and feeding studies
Gastric emptying in Kunming mice was measured using paracetamol absorption test. As shown in Fig. 3D , Lip-Di-GLP-1 signicantly reduced the concentrations of paracetamol in plasma, suggesting a potent inhibition of gastric emptying. We next assessed the acute effects of Lip-Di-GLP-1 on food intake. The results revealed that Lip-Di-GLP-1 signicantly reduced food intake in a dose-dependent manner, and the anorectic actions of Lip-Di-GLP-1 were better than synthesized liraglutide (Fig. 3E-G) .
Benecial effects of chronic treatment of Lip-Di-GLP-1 in db/ db mice To evaluate the chronic treatment effects of Lip-Di-GLP-1, 8 week-old db/db mice were once-daily treated with Lip-Di-GLP-1 or twice-daily treated with synthesized liraglutide for 6 weeks. Compared to the control group at day 45, treatment with Lip-Di-GLP-1 prevented the increasing of reliable glucose marker HbA1c and led to a signicantly lower value of $3.9%, better than synthesized liraglutide ($2.3%, Fig. 4A and B) . Furthermore, chronic Lip-Di-GLP-1 treatment resulted in signicant improvements in food intake, body weight, non-fasting blood glucose and fasting insulin levels as compared with control, and to a greater extent than synthesized liraglutide (Fig. 4C-F) . In (Fig. 4G) . The high IOD values of insulin in Lip-Di-GLP-1 group in histological analysis further proved that the improved glucose tolerance induced by Lip-Di-GLP-1 was attributed to its protective effect on pancreas islets (Fig. 5) . Signicantly, the AST, ALT, Scr and BUN values in Lip-Di-GLP-1 group aer the six weeks' treatment were similar to that observed in saline and liraglutide groups, indicating the low toxicities of Lip-Di-GLP-1 on kidney and liver (Fig. 6 , more details referring to the ESI †).
Discussion
In the present study, we combined dimerization and lipidization strategies as a novel means to develop efficient GLP-1-based anti-diabetics with enhanced and prolonged hypoglycemic efficacies. We produced high GLP-1R activation potency, long-acting GLP-1 analogues, that is, Di-GLP-1 (dimerized GLP-1) and Lip-Di-GLP-1 (lipidated Di-GLP-1). Firstly, the Ala 8 in GLP-1 was replaced with Gly to avoid DPP-IV degradation, and an additional Cys was introduced to the C-terminal of GLP-1, and Gly 8 -Cys 31 -GLP-1 was rstly constructed. Then Di-GLP-1 and Lip-Di-GLP-1 were successfully obtained using cysteinemaleimide specic coupling reactions using Gly 8 -Cys 31 -GLP-1, bis-maleimide amine, and activated palmitic acid.
Dimerization was viewed as a useful tool to boost ligandreceptor interaction, and peptide drugs were oen found possess enhanced binding affinities and higher therapeutic potencies than their monomers.
14 We found that Di-GLP-1 had higher GLP-1R activation potency than GLP-1, and the potency of Lip-Di-GLP-1 was only slightly reduced by the presence of palmitic acid, as compared with Di-GLP-1. The conjugation position of fatty acid in peptide has signicant impact on potency, and the negligible reductions observed in receptor activation potency for Lip-Di-GLP-1 indicated that using bismaleimide amine backbone and C-terminal fatty acid conjugations prevented the activity reduction caused by lipidation.
In vivo IPGTT results revealed that the antihypoglycemic efficacies of both Di-GLP-1 and Lip-Di-GLP-1 were signicant better than GLP-1. The following assay in db/db mice further revealed the prominent hypoglycemic and insulinotropic activities of Di-GLP-1 and Lip-Di-GLP-1. Signicantly, consistent with GLP-1-dependent mechanism, the decreased blood glucose concentrations in Di-GLP-1 and Lip-Di-GLP-1 groups were accompanied by the increased plasma insulin levels. The subsequent PK studies revealed that Lip-Di-GLP-1 has 1.8-fold longer t 1/2 and 2.8-fold higher AUC inf value than synthesized liraglutide. PK analysis indicated that dimerization and lipidization not only extended stability but also signicantly increased drug utilization of Lip-Di-GLP-1. The physical interactions of palmitic acid group in Lip-Di-GLP-1 with serum albumin and the increased M w (reduce renal clearance rate) leading by dimerization might be the two main reasons for the enhanced PK behaviors of Lip-Di-GLP-1. The improved PK proles of Lip-Di-GLP-1 were also manifested in hypoglycemic duration studies. The dose-response studies revealed that the antidiabetic durations of Lip-Di-GLP-1 were signicant higher than synthesized liraglutide, and could up to $36 h (100 nmol kg À1 ) in db/db mice. We can envision that the hypoglycemic durations of Lip-Di-GLP-1 would be longer than 2 days in human, as the much faster metabolic rate in mice than human. GLP-1R agonists induced weight loss is part attributed to their inhibitory effects on gastric emptying. 15 The results in paracetamol absorption test showed that Lip-Di-GLP-1 potently inhibited gastric emptying. In feeding studies, Lip-Di-GLP-1 also potently inhibited food intake, and showed better anorectic effects than synthesized liraglutide, and this might attributed to the longer t 1/2 and better gastric emptying inhibitory effect of Lip-Di-GLP-1. Finally, the 6 weeks' treatment of Lip-Di-GLP-1 in db/db mice completely prevented the increase in blood glucose levels and HbA1c, suggesting potent effects on ameliorate hyperglycemic state of db/db mice. The protection of b-cell survival is one of the important characteristics of GLP-1, as such, immunohistochemistry analysis was performed. The signicantly increased insulin IOD values in Lip-Di-GLP-1 group revealed the potent protective effects of Lip-Di-GLP-1 on pancreas, and also explained the improved glucose tolerance caused by Lip-Di-GLP-1 treatment. The benecial effects of LipDi-GLP-1 in long-term treatment were in agreement with other GLP-1R agonists by chronic peripherally administered. 16 The similar values of indexes for kidney and liver toxicity between Lip-Di-GLP-1, saline and synthesized liraglutide groups indicating the safety of Lip-Di-GLP-1.
Conclusion
Summarizing, we described the design and using of Di-GLP-1 and Lip-Di-GLP-1 as novel GLP-1R agonists. Compared with synthesized liraglutide, Lip-Di-GLP-1 has better pharmacokinetics, prominent greater hypoglycemic durations, and more benecial effects on chronic treatment. Accordingly, more consistent efforts should be taken to discover benecial effect and potential of Lip-Di-GLP-1 to serve as a long-acting treatment for T2DM.
Experimental

Materials
Chemical synthesized GLP-1(7-36)-NH 2 and liraglutide were purchased from the GL Biochem Ltd. (Shanghai, China). Biotechnological liraglutide was purchased from the KMD Bioscience Ltd. (Tianjing, China). Bis-maleimide amine (M w ¼ 546.3) was obtained from the Xi'an Ruixi Biological Technology Co., Ltd (Xi'an, China). Mouse insulin ELISA kit and cAMP dynamic kit were purchased from Nanjing Jiancheng Bioengineering Institute (Jiangsu, China) and CIS Bio International (Bedford, USA), respectively. Other reagents, unless otherwise indicated, were purchased from Sigma-Aldrich Co. (St. Louis, MO).
Animals
Normal male Kunming mice (20-28 g) were purchased from Qinglongshan Animal Breeding Farm (Nanjing, China). The reason to use Kunming mice included that they have strong disease resistance and adaptability, high reproductive rate and survival rate, and low price. Thus, Kunming mice were widely used in pharmacology, toxicology and other elds in China. BKS.Cg-Dock7 m+/+ Lepr db /J (db/db) mice (male, 7-8 weeks) were purchased from Model Animal Research Center of Nanjing University (Nanjing, China). Mice (6 per cage) were housed in groups and maintained in a 12 h light/dark cycle and food and water were provided ad libitum. All mice were acclimatized for 1 week before experiment. All experimental procedures were approved by Jiangsu Normal University ethical committee and performed as humane as possible in accordance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (revised 2011) and the Laboratory Animal Management Regulations in China.
Preparation of Di-GLP-1 and Lip-Di-GLP-1
Di-GLP-1 was synthesized by using chemoselective Michael additions between thiol and maleimide groups using bismaleimide amine and the cysteine residue, using a pervious described method. 8 In brief, Gly 8 -Cys 31 -GLP-1 was synthesized using solid phase synthesis using Fmoc synthesis strategy (Fig. S1 , see ESI †) on semi-automatic peptide synthesizer (PSI-200). For Di-GLP-1, Gly 8 -Cys 31 -GLP-1 (2 eq.) was reacted with bis-maleimide amine (1 eq.) in methanol containing DIPEA. For Lip-Di-GLP-1, NHS activated palmitic acid was reacted with bismaleimide amine rst, then Gly 8 -Cys 31 -GLP-1 (2 eq.) was added and using the same synthesis procedure described above (Fig. S2, see ESI †) . The reaction solution was directly injected into preparative reversed-phase HPLC to obtain puried products, and the products were characterized by Bruker MicroTOF Q2 using ESI ionization method.
Receptor activation potencies of Di-GLP-1 and Lip-Di-GLP-1 to HEK293 cells
The GLP-1 receptor activation potencies of Di-GLP-1 and Lip-Di-GLP-1 were evaluated using a pervious described method using HEK293 cells which stably expressing GLP-1 receptor. 17 Briey, cells were cultured in DMEM (Invitrogen) with supplement at 37
C. Serial dilutions of tested peptides were added to 96-well plates containing HEK293 cells. Following incubation, the HTRF reagents (kit components) were added and the plates were incubated for 60 min. The uorescence ratio at 665/ 620 nm (expressed as delta F%) were determined on EnVision (PerkinElmer), and cAMP concentrations were calculated using standard curve by plotting delta F% versus cAMP concentration for every experiment. )
. Tail blood glucose levels were measured using a handheld glucometer (Sannuo, China) at À15, 0, 15, 30, 45, 60 and 120 min.
IPGTT and insulinotropic assay in db/db mice db/db mice (7 weeks, n ¼ 6) were fasted overnight to ensure the blood glucose levels below 10 mmol L À1 , and then i.p. Di-GLP-1 were s.c. administrated. At each predetermined times (1, 2, 3, 4, 6, 12, 24 and 36 h), there mice were sacriced and $200 mL of blood samples were collected into EDTA containing tubes through extracting eyeball. Plasma was obtained using the above described method and immediately frozen until analysis via LC-MS/MS using a previous described method. ) was added and incubated for 5 h. The absorbance at 570 nm was measured using the Thermo multiwall spectrophotometer (Waltham, MA, USA). The absorbance in the control cells was set as 100%, and the absorbance values of the saline, liraglutide (chemical), liraglutide (biotechnological), Di-GLP-1 and Lip-Di-GLP-1 were normalized as the percentage of the control value.
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One week toxicity assay in db/db mice
The one week toxicity test of Di-GLP-1 and Lip-Di-GLP-1 was conducted on db/db mice (n ¼ 3), using a previously described method with some modications. Mice were divided into ve groups, before the testing day each group of mice were fasted overnight, and saline, 500 nmol kg À1 of liraglutide (chemical),
liraglutide (biotechnological), and Di-GLP-1 and Lip-Di-GLP-1 were s.c. injected and rodent chow were provided immediately. During the testing period, food and water were provided ad libitum. Tested compound and saline were twice daily administered at 8 AM and 8 PM. At the end of the test, the blood was collected through extracting eyeball (approximately 1 mL) and mice were sacriced. Blood samples were centrifuged to separate serum. The levels of SCr, AST, BUN, and ALT in serum were determined using Beckman Coulter Automatic Analyzer using commercially available kits.
Hypoglycemic duration test
The glucose homeostasis effects of Lip-Di-GLP-1 were evaluated using db/db mice under non-fasting condition. Mice were given free access to food and water during the whole experiment. On the experiment day, the non-fasting blood glucose levels of mice were assessed, and mice with blood glucose levels over 15 mmol L À1 were selected for experimentation. Then mice were divided into 9 groups (n ¼ 6, 8 weeks) with matching non-fasting blood glucose levels, and saline, liraglutide, and Lip-Di-GLP-1 (10, 25 and 100 nmol kg À1 ) were s.c. administrated at 0 h. Blood glucose levels were assessed using the same method described above at 0, 4, 6, 12, 24 and 48 h aer dosing.
Gastric emptying study
Kunming mice (n ¼ 6) were fasted for 6 h, and mice were injected (i.p.) with saline, liraglutide and Lip-Di-GLP-1 (25 nmol kg À1 ) 30 min prior to oral administration of paracetamol (100 mg kg À1 , 0 min). 21 Tail vein blood ($50 mL) was collected into heparin containing tubes at 15, 30, and 60 min. Plasma were separated using the same method described above and the concentration of paracetamol were analyzed by LC-MS/MS.
Food intake studies db/db mice (n ¼ 6, 7 weeks) were individual housed and fasted for 16 h before the food intake studies. Mice were s.c. injected with liraglutide, Lip-Di-GLP-1 (10, 25 and 100 nmol kg À1 ) and saline. Then premeasured amount of food (standard rodent chow) were placed in the cage immediately and mice were allowed free access to food and water. Food intake was measured at 0, 6, 12, 24 and 48 h.
Repeated injections of Lip-Di-GLP-1 in db/db mice Eight-week-old db/db mice (n ¼ 6) were housed individually and separated to three groups according to their HbA1c levels (%) which measured by DCA2000 chemistry analyzer (Bayer, USA) through collect blood samples from the tail. According to the PK proles, saline (control) and liraglutide (25 nmol kg À1 ) were twice daily s.c. administered, and Lip-Di-GLP-1 (25 nmol kg À1 ) was once daily s.c. administered over 6 weeks. Food intake, body weight and blood glucose levels (non-fasting state) were recorded weekly. Fasted insulin levels were measured at days -2, 22 and 43 using the same method as described above. One IPGTT was performed aer 6 weeks treatment. Mice were fasted overnight (16 h), followed by 1 g kg À1 glucose challenging (i.p.) at 0 min. Blood glucose concentrations were measured at 0, 15, 30, 60 and 120 min. At the end of the study, mice were sacriced and blood samples were collected. Blood samples were analyzed for HbA1c (%). Furthermore, several key indicators in serum, including SCr, AST, BUN and ALT were determined using Beckman Coulter Automatic Analyzer using commercially available kits. Aer collect the blood, the pancreases were isolated and insulin immunostaining was carried out using a previously described method. 22 The integrated optical density (IOD) values of insulin were recorded using Image-pro plus soware (version 6.0, Media Cybernetics Inc., USA).
Statistical analysis
Data are expressed as means AE SD. All pharmacology data analyses were conducted by GraphPad (version 5.0) unless indicated otherwise. Statistical signicances between multiple groups were determined using one-way ANOVA with post hoc Tukey's tests. P values < 0.05 were considered statistically signicant.
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